Beta-blocker treatment can lead to a modest increase in depressive symptoms among patients who have myocardial infarction with preserved left ventricular ejection fraction (LVEF).

The stock options are subject to the terms and conditions of the Tenaya Therapeutics Inc. 2024 Inducement Equity Incentive Plan and related forms of agreements, and were granted as an inducement ...

A new study by researchers at Intermountain Health in Salt Lake City finds that 40 percent of newly diagnosed heart failure patients also have atrial fibrillation – a combination of cardiac disorders ...

Tirzepatide is a long-acting dual glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 receptor agonist.

Approximately €70 Million in Upfront and Near-term Payments to Cytokinetics Up to €490 Million in Commercial Milestone Payments, with<br / ...

The trial met both primary endpoints, with tirzepatide showing a 38% decrease in heart failure outcomes compared to placebo.

According to research conducted by Johns Hopkins University, a form of heart failure known as heart failure with a preserved ejection fraction or HFpEF is responsible for more than half of all heart ...

The use of sodium-glucose cotransporter 2 (SGLT2) inhibitors in US patients hospitalized with heart failure (HF) and a left ...

Detailed results were announced from a phase 3 clinical trial evaluating the use of tirzepatide in adults with heart failure with preserved ejection fraction (HFpEF) and obesity. The multicenter, ...

The company develops TNX-101 (IV), TNX-102, and TNX-103 (levosimendan) that have completed phase II clinical trials for the treatment of patients with pulmonary hypertension associated with heart ...

Popular anti-obesity drugs continue to show cardiovascular benefits beyond weight loss, according to several new papers ...